Findings

What do systematic reviews say?

219 questions · 228 findings · 18 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 36 · 15.8%GRADE not reported 9 · 3.9%Very low 30 · 13.2%Low 71 · 31.1%Moderate 60 · 26.3%High 22 · 9.6%

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Cardiac index · people with pulmonary hypertension due to CTEPH

2 findings from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low
Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

PVR · people with pulmonary hypertension due to CTEPH

2 findings from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low
Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

PAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 453 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension group 2 ‐ 4

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i probably leads to higher improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 11.31 [4.9, 26.14]
2 studies · 146 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension group 2 ‐ 4

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

PASP · people with pulmonary hypertension group 2 ‐ 4

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 146 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

RAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 341 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 239 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 266 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.2 [0.66, 2.17]
2 studies · 227 participants
Moderate

PDEI vs placebo

IPSS‐total score

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 4293 participants
Low

PDEI plus alpha‐blocker vs PDEI alone

IPSS‐total score

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

PDEI plus alpha‐blocker vs PDEI alone

BPHII score

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PDEI plus alpha‐blocker vs PDEI alone

Adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PDEI + 5‐ARI vs 5‐ARI alone

IPSS‐total score

2 findings from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 695 participants
Moderate
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 695 participants
Moderate

PDEI + 5‐ARI vs 5‐ARI alone

BPHII score

The review found no eligible studies for this question.

2 findings from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PDEI + 5‐ARI vs 5‐ARI alone

Adverse events

The review found no eligible studies for this question.

2 findings from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 1.07 [0.84, 1.36]
1 study · 695 participants
Low

PDEI vs placebo

BPHII score

1 finding from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 3646 participants
Low